The STELLAR-303 trial shows zanzalintinib plus atezolizumab significantly improves overall survival in refractory metastatic colorectal cancer, offering a new immunotherapy-based treatment option.
Most Recent Articles
Personalizing Colon Cancer Treatment: The Role of Circulating Tumor DNA
The DYNAMIC-III trial reveals how ctDNA-guided adjuvant therapy impacts recurrence-free survival and treatment toxicity in stage III colon cancer, highlighting future challenges.
Innovating Stroke Research: Integrating AI, Platform, and Pragmatic Trial Designs
Explore the opportunities and challenges of integrating artificial intelligence and novel trial designs to revolutionize acute ischemic stroke research and clinical care.
Beyond Traditional Risk Factors: VAT and Hepatic Fat’s Impact on Carotid Health
Explore how visceral adipose tissue and hepatic fat independently influence carotid atherosclerosis, beyond traditional risk factors, according to findings from major cohort studies.
RBM20 ASOs: A Novel Therapeutic Approach for HFpEF Diastolic Dysfunction
Discover how RBM20 antisense oligonucleotides alleviate diastolic dysfunction in a mouse model of cardiometabolic heart failure, offering a novel therapeutic strategy for HFpEF.